• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBrainstorm Health

Brainstorm Health Daily: April 3, 2017

By
Clifton Leaf
Clifton Leaf
and
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Clifton Leaf
Clifton Leaf
and
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
April 3, 2017, 4:34 PM ET

Greetings, readers. Sy filling in today, Cliff will be back imminently.

In today’s edition, we’ll be tackling the right songs to listen to in order to prep yourself for an unexpected CPR session; more details about the technology used to birth the world’s first “three-parent baby;” and the continued saga of states attempting to shore up Obamacare in a time of intense uncertainty surrounding the health law.

Read on for the day’s news.

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

DIGITAL HEALTH

The team behind the world’s first three-person baby pulls back the curtain. Last April, Dr. John Zhang and his team achieved a remarkable milestone as the world’s first "three parent baby" was born. The child was conceived through a technique that involved taking the cellular nucleus from the mother's egg, inserting it into a donor egg that had its nucleus removed, and then fertilizing this egg (which contained the mother's DNA but not genetic mitochondrial defects) before inserting it back into the mother. The procedure brought up some ethical concerns at the time - but the technique has since been officially sanctioned in the U.K. Zhang, a doctor at the New Hope Fertility Center in New York, and his team have now published more information about the procedure in the journal Reproductive Biomedicine Online. And it's not all necessarily good news despite its landmark nature. "The paper reports new details about the procedure, such as the method used to transfer the mitochondria: freezing and heating the embryo before using an electrical pulse to fuse the mother's nucleus into the donor egg," writes Nature. "The study also reveals that some diseased DNA from the mother was carried over inadvertently into the donor egg, which could have long-term repercussions for the child's health." Researchers will reportedly not continue to conduct more mitochondrial tests on the baby boy unless medically necessary. Zhang has insisted the parents received sufficient counseling and his team will continue testing the technique. (Nature)

Kite files CAR-T therapy in continuing race with Novartis. Kite Pharma has filed a marketing application for its next-gen chimeric antigen receptor T-cell (CAR-T) blood cancer therapy, just days after rival Novartis scored a "priority review" of its own rival treatment that could speed up the regulatory process considerably. Novartis and Kite have been jockeying to become the first company to have such a therapy, which involves reconfiguring immune cells to sniff out and kill cancers before they are inserted into patients, on the U.S market. At this point, Novartis still appears to have the edge. But it's unclear how much that would matter given the existing uncertainties surrounding the CAR-T market, including whether doctors and insurers will be all that eager about them given the therapies' high prices and scaleability issues (since these cells have to be extracted from individual patients, re-engineered, multiplied, and then re-inserted).

INDICATIONS

Astellas snaps up a Belgian pharma for $853 million with eyes on a drug for hot flashes. U.S.-based Astellas Pharma is buying privately-held Belgian biotech Ogeda SA for $533 million upfront in a deal that could eventually be valued at $853 million. Astellas' main goal here is to get its hands on an experimental Ogeda treatment for hot flashes and night sweats associated with women going through menopause. If the therapy, fezolinetant, crosses certain regulatory thresholds, Ogeda could net another $320 million. "The transaction fits with our strategy to deliver innovative drugs in therapeutic areas with high unmet medical needs," said Astellas president and CEO Yoshihiko Hatanaka in a statement.(Chicago Tribune)

More EpiPens are getting recalled. Mylan already had a bit of headache on its hands with the ongoing international recall of some 81,000 EpiPens throughout the world (on top of, you know, the whole price gouging controversy). Well, the Food and Drug Administration (FDA) announced over the weekend that Meridian Medical Technologies (a manufacturer of Mylan's EpiPen) is voluntarily recalling 13 lots of the life-saving, allergy-busting device in the wake of potentially defective parts. "While the number of reported failures is small, EpiPen products that potentially contain a defective part are being recalled because of the potential for life-threatening risk if a severe allergic reaction goes untreated," said the FDA in a statement.(CNN)

THE BIG PICTURE

How states are trying to stabilize their Obamacare marketplaces. At least two states - Minnesota and Alaska - are taking matters into their own hands when it comes to stabilizing premiums in Obamacare's marketplaces. On Monday, Democratic Minnesota Gov. Mark Dayton told state legislative leaders that he would allow a bill to pass, albeit without his signature, that would provide health insurance companies more than $540 million in reinsurance funds in an effort to bring down premiums in the state's individual Obamacare market. This is partly an effort to convince insurers not to retrench from the health law's exchanges in Minnesota, and could potentially bring down premiums significantly. Dayton still expressed some reticence about the bill over funding sources but said he would not veto it. In the meantime, the Trump administration is reportedly negotiating with the conservative House GOP Freedom Caucus (which helped sink Trumpcare) over ways to dismantle Obamacare administratively, including by nixing Affordable Care Act provisions which mandate that insurance companies provide certain types of benefits and "community rating" that keeps costs lower for older and sicker Americans.

Could a song help save your life? Administrating CPR is no joke. In a life-and-death situation, you have to deliver constant, forceful pumps to the chest at the rate of about 100 beats per minute. That can be pretty difficult to gauge under pressure. But at least one firm is trying to give layman heroes some critical training tools: music. New York-Presbyterian hospital has created a website with crucial information about how to perform CPR - as well as a a link to a Spotify playlist dubbed "Songs to do CPR to" that includes various pop hits that clip at the 100 to 120 beats per minute range. Some choice selections: Stayin' Alive by the Bee Gees and Rock Your Body by Justin Timberlake. Oh, and lest you think we're making light of such a serious scenario: you're not actually supposed to listen to this music while performing CPR. Just keep it in mind as a handy mental metronome.(NPR)

REQUIRED READING

Why China Is a Healthy Investment, by Joseph Jimenez

9 Health Gadgets for Better Sleep and Productivity, by Lisa Eadicicco

It Pays to Shun Your Digital Inbox, by Adam Lashinsky

Google’s Android Just Beat Microsoft Windows As Most Popular OS, by Lucinda Shen

Produced by Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

Find past coverage. Sign up for other Fortunenewsletters.
About the Authors
By Clifton Leaf
See full bioRight Arrow Button Icon
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

FDA
HealthDrugs
Female libido pill gets expanded approval for menopause by FDA
By Matthew Perrone and The Associated PressDecember 15, 2025
1 hour ago
HealthCommentary
Nicotine pouches offer huge promise—so long as the U.S. doesn’t repeat its mistake with vaping
By Max CunninghamDecember 14, 2025
1 day ago
Thompson
C-SuiteMedia
Atlantic CEO Nick Thompson on how he learned to ‘just keep moving forward’ after his famous firing at 22
By Nick LichtenbergDecember 14, 2025
1 day ago
HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
2 days ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
2 days ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
3 days ago

Most Popular

placeholder alt text
Success
'I had to take 60 meetings': Jeff Bezos says 'the hardest thing I've ever done' was raising the first million dollars of seed capital for Amazon
By Dave SmithDecember 15, 2025
7 hours ago
placeholder alt text
Success
Meetings are not work, says Southwest Airlines CEO—and he’s taking action, by blocking his calendar every afternoon from Wednesday to Friday 
By Preston ForeDecember 15, 2025
9 hours ago
placeholder alt text
Success
Sorry, six-figure earners: Elon Musk says that money will 'disappear' in the future as AI makes work (and salaries) irrelevant
By Orianna Rosa RoyleDecember 15, 2025
11 hours ago
placeholder alt text
AI
Deloitte's CTO on a stunning AI transformation stat: Companies are spending 93% on tech and only 7% on people
By Nick LichtenbergDecember 15, 2025
14 hours ago
placeholder alt text
Uncategorized
Transforming customer support through intelligent AI operations
By Lauren ChomiukNovember 26, 2025
19 days ago
placeholder alt text
Real Estate
A 'new era' in the housing market is about to begin as affordability finally improves 'for the first time in a bunch of years,' economist says
By Jason MaDecember 14, 2025
1 day ago